NeuronFeed Submit a startup
Startups/ AI Healthcare/ OpenEvidence

OpenEvidence

Verified

AI medical assistant for clinicians

San Francisco, United States Founded 2022
Visit website
NeuronScore 60/100
Total Raised $735M 4 rounds
Valuation $12B
Stage Series d Jan 2026
Team 50-200 since 2022
AI HealthcareAI MedicalAI Search #Enterprise#Freemium#LLM
About OpenEvidence

OpenEvidence is an AI medical assistant trusted by over 700,000 physicians — making it one of the most widely adopted AI tools in healthcare. Built on a specialised medical LLM trained on clinical literature, guidelines, and drug databases, OpenEvidence answers complex clinical questions with cited, evidence-graded responses. Physicians use it at the point of care for diagnosis, dosing, and treatment decisions, reducing reliance on outdated references.

NeuronScore Signal quality across funding, news, traction & verification
60 /100
Strong
Funding momentum
25/30
Active deals
0/10
News
5/12
Traffic
4/8
Verified
17/20
Freshness
0/10
Agent-Ready Score 40/100 · checked May 3, 2026
MCP
Public API
Webhooks
OAuth2
SDK · TS
SDK · Py
SDKs: TypeScriptPython
Funding History 4 rounds · $735M total
Jan 2026 Series d $250M
Oct 2025 Series c $200M
Jul 2025 Series b $210M
Feb 2025 Series a $75M
Team 2 operators
ceo & co-founder
News & Coverage 1 mention All →
Alternatives 6 similar All →
FAQ
When was OpenEvidence founded?
OpenEvidence was founded in 2022 in San Francisco, United States.
How much funding has OpenEvidence raised?
OpenEvidence has raised $735M across 4 rounds — most recently a Series d in Jan 2026.
What is OpenEvidence's valuation?
Most recent disclosed valuation is $12B.
How much does OpenEvidence cost?
OpenEvidence pricing: Free.
Who founded OpenEvidence?
Daniel Nadler and Zachary Ziegler founded OpenEvidence.
Where is OpenEvidence headquartered?
OpenEvidence is headquartered in San Francisco, United States.
Discussion

Sign in to join the discussion.

Sign in →

No comments yet — be the first.

Contextual paths to related AI startups, deals and rankings.